Drug developer AstraZeneca said Friday the Food and Drug Administration approved an extended-release version of the bipolar-disorder drug Seroquel.
The new version of the drug, called Seroquel XR, is approved as a once-daily treatment for bipolar mania, biopolar depression and mixed biopolar episodes. The previous version of the drug had to be taken twice-daily for bipolar mania and is not approved for mixed episodes.
Seroquel XR is also approved as a long-term treatment for bipolar I disorder.
Shares of AstraZeneca fell 35 cents to $36.20 in morning trading.
The new version of the drug, called Seroquel XR, is approved as a once-daily treatment for bipolar mania, biopolar depression and mixed biopolar episodes. The previous version of the drug had to be taken twice-daily for bipolar mania and is not approved for mixed episodes.
Seroquel XR is also approved as a long-term treatment for bipolar I disorder.
Shares of AstraZeneca fell 35 cents to $36.20 in morning trading.
0 comments:
Post a Comment